NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value Euro 0.12 per share (NAMS)

Historical Holders from Q4 2022 to Q3 2025

Symbol
NAMS on Nasdaq
Type / Class
Equity / Ordinary Shares, nominal value Euro 0.12 per share
Shares outstanding
114M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
120M
Holdings value
$3.42B
% of all portfolios
0.011%
Grand Portfolio weight change
+0%
Number of holders
134
Number of buys
67
Number of sells
-54
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value Euro 0.12 per share (NAMS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $205M $3.48M 11.1M +1.73% RA Capital Management, L.P. 31 Mar 2025
Capital World Investors 8.7% +15% $279M $40.8M 9.82M +17.1% Capital World Investors 30 Sep 2025
Forbion Capital Fund IV Cooperatief U.A. 8.3% -12.2% $223M -$30.2M 9.32M -11.9% ForGrowth NAP B.V. 26 Sep 2025
Frazier Life Sciences X, L.P. 7.7% +17.1% $245M $36.9M 8.62M +17.7% Frazier Life Sciences Public Fund, L.P. 01 Nov 2025
VIKING GLOBAL INVESTORS LP 6.5% $129M 6.98M VIKING GLOBAL INVESTORS LP 31 Dec 2024
BCLS II Investco, LP 4.7% -52.9% $214M -$241M 5.38M -52.9% BCLS Fund III Investments, LP 02 Dec 2025

Institutional Holders of NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value Euro 0.12 per share (NAMS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 120M $3.42B +$123M $28.44 134
2025 Q2 116M $2.11B +$92.2M $18.11 130
2025 Q1 111M $2.28B +$248M $20.47 126
2024 Q4 98.6M $2.53B +$570M $25.70 130
2024 Q3 77.1M $1.28B +$65.9M $16.60 100
2024 Q2 72M $1.38B -$7.91M $19.21 90
2024 Q1 72.2M $1.71B +$242M $23.65 76
2023 Q4 61.9M $691M -$81.2K $11.17 32
2023 Q3 50.2M $464M +$5.44M $9.25 35
2023 Q2 48.8M $581M +$184M $11.89 29
2023 Q1 33.3M $445M +$689K $13.26 19
2022 Q4 33.5M $362M +$362M $10.90 14